相当大比例的慢性非癌性疼痛 (CNCP) 患者接受他喷他多 (TAP) 或羟考酮/纳洛酮 (OXN) 治疗，以随着时间的推移改善他们的身心健康状况。一项横断面研究对 135 名 CNCP 门诊患者进行了一项横断面研究。在西班牙三级医院开处方（TAP：n = 58，OXN：n = 77），以比较与健康相关的生活质量 (HRQoL) 记录。健康实用程序源自 EQ-5D-3L。建立回归模型来寻找其他 HRQoL 决定因素。疼痛强度、缓解情况、镇痛处方、不良事件、住院时间、急诊科就诊以及止痛药处方的变更均通过电子记录进行登记。两种阿片类药物的健康效用（0.43 ± 0.24 分，从 -0.654 到 1）相似，尽管与 OXN 相比，TAP 的每日阿片类药物剂量需求、神经调节剂的使用和便秘副作用均显着降低。多变量调整后，HRQoL 受损的显着预测因素是疼痛强度（β = -0.227，95% CI -0-035 至 -0.005）、不良事件数量（β = -0.201，95% CI -0.024 至 -0.004）和阿片类药物每日剂量（β = -0.175，95% CI -0.097 至 -0.012）。未来的研究应考虑男性 (β = -0.044) 和疼痛缓解 (β = 0.158)。在现实世界的 CNCP 患者中，TAP 和 OXN 的 HRQoL 相似，尽管具有 TAP 阿片类药物节约效应。需要开展更多工作来探索与 CNCP 中长期使用阿片类药物相关的 HRQoL 决定因素。版权所有 © 2024 国际卫生经济学和结果研究学会。由爱思唯尔公司出版。保留所有权利。

A substantial proportion of patients with chronic noncancer pain (CNCP) are treated with tapentadol (TAP) or oxycodone/naloxone (OXN) to improve their perceived physical and mental health over time.A cross-sectional study was conducted in 135 CNCP outpatients with usual prescribing (TAP: n = 58, OXN: n = 77) at a tertiary-care Spanish Hospital to compare health-related quality-of-life (HRQoL) records. Health utility was derived from the EQ-5D-3L. Regression models were performed to search for other HRQoL determinants. Pain intensity, relief, analgesic prescription, adverse events, inpatient stays, emergency department visits, and change to painkiller prescriptions were registered from electronic records.Health utility (0.43 ± 0.24 scores, from -0.654 to 1) was similar for both opioids, although TAP showed a significantly low daily opioid dose requirement, neuromodulators use, and constipation side effect compared with OXN. After multivariable adjustment, the significant predictors of impaired HRQoL were pain intensity (β = -0.227, 95% CI -0-035 to -0.005), number of adverse events (β = -0.201, 95% CI -0.024 to -0.004), and opioid daily dose (β = -0.175, 95% CI -0.097 to -0.012). Male sex (β = -0.044) and pain relief (β = 0.158) should be taken into account for future studies.HRQoL was similar for TAP and OXN in real-world patients with CNCP, albeit with a TAP opioid-sparing effect. More work is needed to explore HRQoL determinants in relation to long-term opioid use in CNCP.Copyright © 2024 International Society for Health Economics and Outcomes Research. Published by Elsevier Inc. All rights reserved.